{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:47:43Z","timestamp":1715579263284},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1007\/s11886-004-0073-0","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T09:47:26Z","timestamp":1180172846000},"page":"259-263","source":"Crossref","is-referenced-by-count":4,"title":["Eplerenone: Will it have a role in the treatment of acute coronary syndromes?"],"prefix":"10.1007","volume":"6","author":[{"given":"David J.","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"73_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","volume":"104","author":"P Libby","year":"2001","unstructured":"Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365\u2013372.","journal-title":"Circulation"},{"key":"73_CR2","first-page":"C30","volume":"19","author":"G Noll","year":"1998","unstructured":"Noll G, Luscher TF: The endothelium in acute coronary syndromes. Eur Heart J 1998, 19:C30-C38.","journal-title":"Eur Heart J"},{"key":"73_CR3","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.98.15.1481","volume":"98","author":"JE Freedman","year":"1998","unstructured":"Freedman JE, Ting B, Hankin B, et al.: Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998, 98:1481\u20131486.","journal-title":"Circulation"},{"key":"73_CR4","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.101.14.1722","volume":"101","author":"MJ Somers","year":"2000","unstructured":"Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101:1722\u20131728. Free radical production in response to DOCA through superoxide generating NADH\/NADPH oxidases.","journal-title":"Circulation"},{"key":"73_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425\u2013431. A randomized, placebo-controlled, double-blind crossover study that showed the acute short-term systemic administration of aldosterone results in endothelial vasodilator dysfunction in normal men, providing evidence for an aldosterone-induced vasculopathy.","journal-title":"Clin Sci (Lond)"},{"key":"73_CR6","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","volume":"108","author":"SL Liu","year":"2003","unstructured":"Liu SL, Schmuck S, Chorazcyzewski JZ, et al.: Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400\u20132406. Study demonstrating rapid nongenomic effects of aldosterone in aortic vascular rings and in cultured endothelial cells.","journal-title":"Circulation"},{"key":"73_CR7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597. A randomized, placebo-controlled, double-blind crossover study on 10 patients with New York Heart Association class II-III chronic heart failure on standard diuretic\/ACE inhibitor therapy, comparing 50 mg\/d spironolactone (1 mo) versus placebo, which demonstrated improvements in endothelial function following 4 weeks of therapy.","journal-title":"Circulation"},{"key":"73_CR8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.HYP.37.2.801","volume":"37","author":"T Quaschning","year":"2001","unstructured":"Quaschning T, Ruschitzka F, Shaw S, Luscher TF: Aldosterone receptor antagonism normalizes vascular function in liquoriceinduced hypertension. Hypertension 2001, 37:801\u2013805. This study demonstrates that MR antagonism normalizes blood pressure, prevents upregulation of vascular endothelin-1, and restores endothelial dysfunction in 11b-HSD2-deficient (licorice-induced) hypertension.","journal-title":"Hypertension"},{"key":"73_CR9","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212\u20132216. MR antagonism with eplerenone improves endothelial function and reduces superoxide generation in diet-fed hyperlipidemia","journal-title":"Circulation"},{"key":"73_CR10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT, Jr.: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232\u2013237.","journal-title":"Hypertension"},{"key":"73_CR11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun Y, Zhang J, Lu L, et al.: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002, 161:1773\u20131781. This study demonstrates that chronic aldosterone\/salt treatment is accompanied by time-dependent sustained increases in oxidant stress, activation of redox-sensitive transcription factors, and inflammatory cell infiltration, leading to a proinflammatory\/fibrogenic phenotype. Spionolactone, PDTC, and NAC each attenuated these responses.","journal-title":"Am J Pathol"},{"key":"73_CR12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"Virdis A, Neves MF, Amiri F, et al.: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40:504\u2013510. Spironolactone was found to partially correct structural and functional abnormalities in response to angiotensin II and reduced vascular NADPH oxidase activity and plasma markers of oxidative stress.","journal-title":"Hypertension"},{"key":"73_CR13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","volume":"41","author":"S Keidar","year":"2003","unstructured":"Keidar S, Hayek T, Kaplan M, et al.: Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41:955\u2013963. Administration of eplerenone reduces oxidative stress and atherosclerosis progression in apolipoprotein E-deficient mice.","journal-title":"J Cardiovasc Pharmacol"},{"key":"73_CR14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135\u20131143.","journal-title":"Circulation"},{"key":"73_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458.","journal-title":"Hypertension"},{"key":"73_CR16","doi-asserted-by":"crossref","first-page":"R328","DOI":"10.1152\/ajpregu.00376.2002","volume":"284","author":"J Francis","year":"2003","unstructured":"Francis J, Weiss RM, Johnson AK, Felder RB: Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol 2003, 284:R328-R335.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"73_CR17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","volume":"37","author":"A Fiebeler","year":"2001","unstructured":"Fiebeler A, Schmidt F, Muller DN, et al.: Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 2001, 37:787\u2013793.","journal-title":"Hypertension"},{"key":"73_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","volume":"104","author":"E Harada","year":"2001","unstructured":"Harada E, Yoshimura M, Yasue H, et al.: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001, 104:137\u2013139.","journal-title":"Circulation"},{"key":"73_CR19","first-page":"336","volume":"85","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Kim KS, Chen YQ, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor- 1 production. J Clin Endocrinol Metab 2000, 85:336\u2013344. This study tests the hypothesis that aldosterone contributes to the regulation of PAI-1 expression by transfecting luciferase reporter constructs containing the human PAI-1 promoter into rat aortic smooth muscle cells. The results support the hypothesis that aldosterone modulates the effect of angiotensin II on PAI-1 expression in vitro and in vivo in humans.","journal-title":"J Clin Endocrinol Metab"},{"key":"73_CR20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/jcem.87.2.7980","volume":"87","author":"P Sawathiparnich","year":"2002","unstructured":"Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002, 87:448\u2013452. This study provides evidence that endogenous aldosterone influences PAI-1 production in humans.","journal-title":"J Clin Endocrinol Metab"},{"key":"73_CR21","first-page":"230","volume":"15","author":"NJ Brown","year":"2002","unstructured":"Brown NJ, Vaughan DE, Fogo AB: Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002, 15:230\u2013235. This review explores the hypothesis that aldosterone causes injury and fibrosis, in part, through effects on PAI-1, the major physiologic inhibitor of plasminogen activators in vivo.","journal-title":"J Nephrol"},{"key":"73_CR22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0037-1613404","volume":"89","author":"A Schafer","year":"2003","unstructured":"Schafer A, Fraccarollo D, Hildemann S, et al.: Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003, 89:1024\u20131030.","journal-title":"Thromb Haemost"},{"key":"73_CR23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355\u20131364.","journal-title":"Circ Res"},{"key":"73_CR24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.HYP.32.3.527","volume":"32","author":"M Usui","year":"1998","unstructured":"Usui M, Ichiki T, Katoh M, et al.: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998, 32:527\u2013533.","journal-title":"Hypertension"},{"key":"73_CR25","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","volume":"42","author":"D Fraccarollo","year":"2003","unstructured":"Fraccarollo D, Galuppo P, Hildemann S, et al.: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003, 42:1666\u20131673. Eplerenone improves left ventricular remodeling in rats with left ventricular dysfunction after extensive MI. Combination therapy with an ACE inhibitor substantially potentiates this effect by a complementary prevention of left ventricular fibrosis, cardiac hypertrophy, and molecular alterations.","journal-title":"J Am Coll Cardiol"},{"key":"73_CR26","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967\u20132972.","journal-title":"Circulation"},{"key":"73_CR27","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700\u20132706.","journal-title":"Circulation"},{"key":"73_CR28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute MI complicated by left ventricular dysfunction and heart failure.","journal-title":"N Engl J Med"},{"key":"73_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","volume":"104","author":"MR Ward","year":"2001","unstructured":"Ward MR, Kanellakis P, Ramsey D, et al.: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001, 104:467\u2013472. Eplerenone attenuates constrictive remodeling after coronary artery angioplasty by mechanisms involving reduction in collagen accumulation.","journal-title":"Circulation"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0073-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-004-0073-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0073-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:00Z","timestamp":1559433360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-004-0073-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s11886-004-0073-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}